BSE Live
Apr 21, 16:01Prev. Close
2328.60
Open Price
2337.95
Bid Price (Qty.)
2311.75 (850)
Offer Price (Qty.)
2330.00 (49)
NSE Live
Apr 21, 15:56Prev. Close
2328.70
Open Price
2333.00
Bid Price (Qty.)
2311.50 (2)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Lupin (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 22,192.11 | 19,656.34 | 16,269.98 | 16,192.79 | 14,926.99 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 22,192.11 | 19,656.34 | 16,269.98 | 16,192.79 | 14,926.99 | |
| Total Operating Revenues | 22,707.90 | 20,010.82 | 16,641.66 | 16,405.48 | 15,162.96 | |
| Other Income | 195.82 | 120.17 | 73.36 | 141.69 | 136.29 | |
| Total Revenue | 22,903.72 | 20,130.99 | 16,715.02 | 16,547.17 | 15,299.25 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 4,457.41 | 4,142.19 | 3,687.81 | 3,235.71 | 3,169.79 | |
| Purchase Of Stock-In Trade | 2,642.62 | 2,958.72 | 2,938.22 | 3,443.85 | 2,677.31 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FGWIP And Stock In Trade | -257.78 | -457.44 | 153.73 | -198.32 | -484.86 | |
| Employee Benefit Expenses | 3,964.20 | 3,494.57 | 3,087.15 | 2,989.30 | 2,825.90 | |
| Finance Costs | 294.87 | 311.61 | 274.30 | 142.77 | 140.64 | |
| Depreciation And Amortisation Expenses | 1,169.26 | 1,196.81 | 880.69 | 1,658.71 | 887.41 | |
| Other Expenses | 6,618.14 | 6,062.26 | 4,976.63 | 6,647.72 | 4,407.94 | |
| Total Expenses | 18,888.72 | 17,708.72 | 15,998.53 | 17,919.74 | 13,624.13 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 4,015.00 | 2,422.27 | 716.49 | -1,372.57 | 1,675.12 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 4,015.00 | 2,422.27 | 716.49 | -1,372.57 | 1,675.12 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 990.69 | 633.85 | 246.42 | 161.15 | 438.47 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -281.95 | -147.15 | 22.38 | -24.00 | 10.05 | |
| Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 708.74 | 486.70 | 268.80 | 137.15 | 448.52 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 3,306.26 | 1,935.57 | 447.69 | -1,509.72 | 1,226.60 | |
| Profit/Loss From Continuing Operations | 3,306.26 | 1,935.57 | 447.69 | -1,509.72 | 1,226.60 | |
| Profit/Loss For The Period | 3,306.26 | 1,935.57 | 447.69 | -1,509.72 | 1,226.60 | |
| Minority Interest | -24.64 | -21.09 | -17.61 | -18.68 | -11.40 | |
| Consolidated Profit/Loss After MI And Associates | 3,281.62 | 1,914.48 | 430.08 | -1,528.04 | 1,216.53 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 72.00 | 42.00 | 9.00 | -34.00 | 27.00 | |
| Diluted EPS (Rs.) | 72.00 | 42.00 | 9.00 | -34.00 | 27.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 364.77 | 182.03 | 181.85 | 295.08 | 271.88 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
20.04.2026
13.04.2026
09.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
12.11.2025
Lupin Standalone September 2025 Net Sales at Rs 4,068.28 crore, down 0.92% Y-o-Y
07.11.2025
Lupin Consolidated September 2025 Net Sales at Rs 7,047.51 crore, up 24.23% Y-o-Y
15.05.2025
Lupin Standalone March 2025 Net Sales at Rs 4,485.67 crore, up 32.09% Y-o-Y
28.02.2025
Lupin Consolidated December 2024 Net Sales at Rs 5,767.71 crore, up 10.97% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth